Share Twitter LinkedIn Facebook Email Pascal Besman, Chief Operating Officer of PharmaMar, shares a Randomized Trial of Topotecan & CAV | Monotherapy Will Have Up to 100 Patients at Annual Meeting 2018 Advertisement
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read